Clinical Trials
216
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (160 trials with phase data)• Click on a phase to view related trials
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
- Conditions
- SCC - Squamous Cell CarcinomaRadiotracerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-10-15
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07217028
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
High-Resolution PET-CT Imaging for Surgical Margin Visualization
- Conditions
- CancerSolid Malignant TumorsSCC - Squamous Cell CarcinomaHNSCCHNSCC,Larynx, Pharynx and Oral Cavity
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06915454
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
- Conditions
- Locally Advanced CancerMetastatic CancerHER2HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaHER 2 Low-expressing Breast Cancer
- Interventions
- Drug: ABY-025 Loading DoseDrug: [68Ga]Ga-ABY-025
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-10-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06828588
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
- Conditions
- HNSCCHNSCC,Larynx, Pharynx and Oral CavitySCC - Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06819228
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
- Conditions
- Clonal Hematopoiesis
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 800
- Registration Number
- NCT06701214
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 43
- Next
News
KRAS G12C Mutations Associated with Shorter Survival in First-Line Metastatic Colorectal Cancer Treatment
A real-world analysis of 12,318 patients with metastatic colorectal cancer revealed that KRAS G12C mutations, present in 3% of cases, were associated with numerically shorter overall survival and progression-free survival compared to non-G12C mutations.
Nanobody Platform Enhances Cancer Immunotherapy Through Albumin Hitchhiking and STING Activation
Vanderbilt researchers developed albumin-hitchhiking nanobodies that extend circulation time from 5 minutes to 55 hours and achieve 11% injected dose per gram tumor accumulation.
Immune Biomarkers Show Promise in Guiding TNBC Treatment Decisions
High levels of tumor-infiltrating lymphocytes (TILs) strongly correlate with improved survival in triple-negative breast cancer patients, with 94% 5-year survival rates observed in patients with TIL levels ≥50%.
Nivolumab Plus Ipilimumab Shows Durable Survival Benefit in Advanced RCC
Eight-year data from CheckMate 214 show nivolumab plus ipilimumab demonstrates long-term efficacy in intermediate- and poor-risk advanced renal cell carcinoma (RCC).
Experts Highlight Critical Treatment Gaps in Metastatic Colorectal Cancer Management
• Despite FDA approval of cetuximab plus encorafenib for BRAF V600E-mutated mCRC, significant challenges remain in treating patients who progress after BRAF inhibitor therapy. • The recent approval of adagrasib with cetuximab for KRAS G12C-mutated mCRC marks progress, but treatment options for other KRAS mutations remain limited, spurring interest in pan-RAS inhibitors. • Refractory mCRC patients without actionable mutations face limited treatment options, emphasizing the crucial role of clinical trials in advancing therapeutic development.